Search results for "Colon"

showing 10 items of 2038 documents

New guidelines for optimal patient care with localized colon cancer: recommending what is proven, but also watching what research is bringing

2020

medicine.medical_specialtyColorectal cancerbusiness.industryFollow up studiesMEDLINEHematologymedicine.diseasePatient careOncologyColonic NeoplasmsmedicineHumansPatient CareIntensive care medicinebusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Response to: Comment on "Feasibility and safety of laparoscopic Complete Mesocolic Excision (CME) for right-sided colon cancer: short-term outcomes. …

2021

medicine.medical_specialtyColorectal cancerbusiness.industryGeneral surgeryMEDLINElaparoscopymedicine.diseaseTerm (time)Clinical studyText miningColonic NeoplasmsmedicineFeasibility StudiesHumansSurgerycomplete mesocolic excisionbusinessMesocolon
researchProduct

A systematic review and meta-analysis comparing surgical and oncological outcomes of upper rectal, rectosigmoid and sigmoid tumours.

2021

Abstract Aim Management paradigms for tumours from the sigmoid colon to the lower rectum vary significantly. The upper rectum (UR) represents the transition point both anatomically and in treatment protocols. Above the UR is clearly defined and managed as colon cancer and below is managed as rectal cancer. This study compares outcomes between sigmoid, rectosigmoid and UR tumours to establish if differences exist in operative and oncological outcomes. Methods Electronic databases were searched for published studies with comparative data on peri-operative and oncological outcome for upper rectal and sigmoid/rectosigmoid (SRS) tumours treated without neoadjuvant radiation. The search adhered t…

medicine.medical_specialtyColorectal cancermedicine.medical_treatmentHealth StatusRectumAnastomotic LeakAnastomosis03 medical and health sciences0302 clinical medicinemedicineHumansNeoplasm MetastasisIntraoperative ComplicationsLymph nodeNeoplasm Stagingbusiness.industryRectal NeoplasmsRectumSigmoid colonCancerGeneral Medicinemedicine.diseaseRadiation therapySurvival RateSigmoid Neoplasmsmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisLymphatic Metastasis030211 gastroenterology & hepatologySurgeryRadiologyNeoplasm GradingNeoplasm Recurrence LocalbusinessEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
researchProduct

Management of rectal cancer in France in a well-defined population.

2014

Objective The aim of this study was to draw a picture of diagnostic assessment and patterns of care for rectal cancer in France using population-based registries data. Methods The study included a random sample of 669 cases of rectal cancers diagnosed in 2005. Results Diagnostic assessment was performed by colonoscopy in 91.4% of the cases. An abdominal computed tomography was performed in 59.4% of the cases and chest computed tomography in 47.8%. An R0 resection was performed in 65.8% of cases and an R1/R2 resection in 16.1%. A rectal endosocography was performed in 40.4% and MRI in 10.4%. The sphincter was preserved in 73.6% of patients aged younger than 75 years of age and in 62.5% of th…

medicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationColonoscopyAnal CanalPreoperative carePreoperative CaremedicineHumansRegistriesStage (cooking)educationAgedNeoplasm Stagingeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryRectal NeoplasmsPalliative CareGastroenterologyAge FactorsChemoradiotherapy AdjuvantColonoscopymedicine.diseaseRadiation therapymedicine.anatomical_structureSphincterRadiologyFrancebusinessTomography X-Ray ComputedChemoradiotherapyEuropean journal of gastroenterologyhepatology
researchProduct

Indications for Performing a Proctologic Examination and Endoscopy

1979

Complaints from the patient about discomfort in the anal region, rectal bleeding, and change in bowel habits — especially recent occurrence of constipation or diarrhea or a change in either symptom — as well as tenesmus are obligatory reasons for conducting a proctologic examination. These symptoms should never be ignored or treated by prescription of hemorrhoid suppositories, antispasmodics, analgesics, or laxatives.

medicine.medical_specialtyConstipationmedicine.diagnostic_testBowel habitbusiness.industryGeneral surgeryAnal Regionmedicine.diseaseInflammatory bowel diseaseColon polypsEndoscopyDiarrheamedicinesense organsMedical prescriptionmedicine.symptomskin and connective tissue diseasesbusiness
researchProduct

The Influence of Infection and Colonization on Outcomes in Inpatients With COVID-19 : Are We Forgetting Something?

2021

The COVID-19 epidemic has been a great challenge to health systems and especially hospitals. A prospective observational epidemiological study was planned as of February 26, 2020 in a tertiary hospital in the Valencia region. The total number of patients followed up with complete information during the first year was 2,448. Among other variables, the comorbidities of the patients were collected (and grouped in the Charson index), the stay in the intensive care unit (ICU), the co-infections, and the colonizations. Data on nosocomial infections due to said virus were also collected. The median days from the onset of symptoms to diagnosis were 4 + 4.6, while an additional 4.4 days had to pass …

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)COVID epidemiologyMedicina preventivaEpidemiologymedicineHumansrisk factorsColonizationEpidemiologiaOriginal ResearchInpatientsForgettingbusiness.industrySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19germ colonizationCandida aurismedicine.diseaseComorbiditySalut públicaIntensive Care UnitsCandida aurisdisease managementEmergency medicineCoinfectionObservational studyPublic HealthPublic aspects of medicineRA1-1270business
researchProduct

P275 Clinical characteristics, associated malignancies and management of primary sclerosing colangitis in inflammatory bowel disease patients: A Span…

2018

medicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryColorectal cancermedicine.medical_treatmentGastroenterologyColonoscopyGeneral MedicineJaundiceLiver transplantationmedicine.diseaseUlcerative colitisInflammatory bowel diseaseTransplantation03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisInternal medicineMedicine030211 gastroenterology & hepatologymedicine.symptombusinessJournal of Crohn's and Colitis
researchProduct

P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease

2021

Abstract Background The role of Vedolizumab (VDZ) as therapeutic option for the postoperative recurrence of Crohn’s disease (CD) following ileocolonic resection is currently unknown. We aimed to assess the effectiveness of VDZ in this setting. Methods All consecutive CD patients with an available baseline colonoscopy at 6-12 months from the ileocolonic resection and treated with VDZ for the postoperative recurrence after the baseline colonoscopy were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). The primary outcome was endoscopic success, assessed at the first colonoscopy following initiation of VDZ. In patients with Rutgeerts score i0 or i1 at …

medicine.medical_specialtyCrohn's diseasemedicine.diagnostic_testbusiness.industryGastroenterologyColonoscopyGeneral Medicinemedicine.diseaseGastroenterologyInflammatory bowel diseaseEndoscopyVedolizumabInternal medicinemedicinebusinessmedicine.drugJournal of Crohn's and Colitis
researchProduct

A phase I-II study of cyclophosphamide, epidoxorubicin, levofolinic acid/5-fluorouracil and recombinant human granulocyte colony stimulating factor i…

1994

Thirty patients with measurable metastatic breast carcinoma were treated with a combination of cyclophosphamide 600 mg/m2 on day 1, levofolinic acid 100 mg/m2 plus 5-fluorouracil 375 mg/m2 on days 1-3, and epidoxorubicin (EDXR) in three refracted doses on days 1-3 with G-CSF rescue for 10 days. In the phase I part of the study, groups of 3 patients received EDXR 20, 25, 30, 35, and 40 mg/m2/day until the dose limiting toxicity (DLT) was reached. At the dose of 40mg/m2/day prolonged grade 4 leukopenia, severe proctitis, and grade 3 diarrhea represented the DLT. All subsequent partients were treated at the maximal tolerated dose of EDXR (35 mg/m2/day). In the group of 18 patients treated at 3…

medicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia Medicamedicine.medical_treatmentLeucovorinBreast NeoplasmsGastroenterologyDrug Administration ScheduleInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineCarcinomaHumansRadiology Nuclear Medicine and imagingCyclophosphamideEpirubicinChemotherapyLeukopeniabusiness.industryCarcinomaHematologyGeneral MedicineLeukopeniaMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryGranulocyte colony-stimulating factorSettore MED/18 - Chirurgia GeneraleRegimenTreatment OutcomeOncologyFluorouracilToxicityFemaleFluorouracilmedicine.symptombusinessmedicine.drugActa oncologica (Stockholm, Sweden)
researchProduct

PHP39 Explaning Differences in EU5 Market Penetration Levels and Rates of Biosimilars: The Case of Epoetine, Granulocyte-Colony Stimulating Factor, a…

2012

medicine.medical_specialtyEndocrinologyInternal medicineHealth PolicymedicinePublic Health Environmental and Occupational HealthBiosimilarBiologyGrowth hormoneGranulocyte colony-stimulating factorMarket penetrationValue in Health
researchProduct